Quick Answer
Outlook Therapeutics, Inc. reported R&D Expense of $27.18 million for fiscal year 2025.
Outlook Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $27.18M | -34.9% |
| 2024 | $41.76M | +57.9% |
| 2023 | $26.45M | -37.5% |
| 2022 | $42.33M | +8.7% |
| 2021 | $38.96M | +47.9% |
| 2020 | $26.34M | +10.7% |
| 2019 | $23.81M | +28.6% |
| 2018 | $18.50M | -22.3% |
| 2017 | $23.81M | -27.3% |
| 2016 | $32.76M | -15.7% |
| 2015 | $38.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $3.63M | -62.4% | -49.1% |
| June 30, 2025 | $7.13M | -36.3% | +61.9% |
| March 31, 2025 | $4.41M | -67.4% | -54.4% |
| December 31, 2024 | $9.66M | +113.3% | -13.8% |
| June 30, 2024 | $11.20M | +0.9% | -17.1% |
| March 31, 2024 | $13.51M | +2378.9% | +198.3% |
| December 31, 2023 | $4.53M | -54.1% | -59.2% |
| June 30, 2023 | $11.10M | -1.3% | +1937.2% |
- Outlook Therapeutics, Inc. showed a decrease of -34.9% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Outlook Therapeutics, Inc.’s r&d expense has declined by 30.1% (from $38.88 million to $27.18 million).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: